Begin main content

Search

We found 54 result(s) for "nivolumab"

Nivolumab for Melanoma

Published on: April 9, 2015
Result type: General Content

Who Might Benefit Melanoma is a cancer of pigment-producing cells that can start in the skin, eye, or mucus membranes. Approximately 6,500 Canadians were diagnosed with new melanoma in 2014, and it is estimated that 1,050 of those will die from the disease. When diagnosed in its earlier stage, melanoma can be cured by surgical removal. However,...

Metastatic Melanoma Gap Analysis

Last Updated: June 8, 2018
Result type: Reports
Product Line: Technology Review

The CADTH pCODR Expert Review Committee (pERC) has issued reimbursement recommendations on immunotherapies (ipilimumab, pembrolizumab, nivolumab, and nivolumab plus ipilimumab) and BRAF mutation targeted therapies (dabrafenib plus trametinib, dabrafenib, vemurafenib, and vemurafenib plus cobimetinib) for the treatment of metastatic melanoma. Alt...

  • Project Number: HE0004-000